मूलभूत आँकड़े
| LEI | 549300UQE748N2H9LE74 |
| CIK | 1446159 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Predictive Oncology Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organiza |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| August 14, 2025 |
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discover |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| July 29, 2025 |
Up to 1,921,706 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-288782 PROSPECTUS Up to 1,921,706 Shares of Common Stock This prospectus relates to the resale from time to time by YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville” or the “Selling Stockholder”) of up to 1,921,706 shares of our Common Stock, par value $0.01 per share (“Common Stock”). The shares of Common Stock to which this |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| July 24, 2025 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 July 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-288782 Requested Date: July 28, 2025 Requested Time |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Predictive Oncology Inc. |
|
| July 18, 2025 |
Exhibit 99.1 EXPLANATORY NOTE Predictive Oncology is revising and recasting certain financial and other information included in its 2024 Form 10-K. The relevant information in the 2024 Form 10-K is being updated to retrospectively reflect the results of the Eagan Business as discontinued operations as a result of meeting the criteria for discontinued operations during the three months ended March |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| July 18, 2025 |
As Filed with the Securities and Exchange Commission on July 18, 2025 As Filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 11, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizatio |
|
| July 8, 2025 |
Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 1, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and PREDICTIVE ONCOLOGY INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individu |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizatio |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 2, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated April 18, 2025 (To Prospectus and Prospectus Supplement dated May 21, 2024) Up to $3,398,000 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated April 18, 2025, to the prospectus, dated |
|
| May 15, 2025 |
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictiv |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organiza |
|
| April 18, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated May 21, 2024) Up to $1,491,000 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of our registration statem |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| April 1, 2025 |
EXHIBIT 99.1 Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update Company continues to progress toward the signing of a definitive merger agreement with Renovaro PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensiv |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2025 |
Predictive Oncology Inc. 2024 Equity Incentive Plan Exhibit 99.1 PREDICTIVE ONCOLOGY INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the 2024 Equity Incentive Plan (the “Plan”) of Predictive Oncology Inc. (the “Company”) is to increase shareholder value and to advance the interests of the Company by furnishing a variety of economic incentives (“Incentives”) designed to attract, retain and motivate employees, certain key consultants and d |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Predictive Oncology Inc. |
|
| April 1, 2025 |
As Filed with the Securities and Exchange Commission on March 31, 2025 As Filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36790 Predictive Oncology Inc. |
|
| March 31, 2025 |
Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 31, 2025 |
Exhibit 19 PREDICTIVE ONCOLOGY INC. POLICY ON AVOIDANCE OF INSIDER TRADING The Board of Directors of Predictive Oncology Inc., a Delaware corporation (the “Company”), has adopted this Insider Trading Policy for our directors, employees (including officers) and consultants with respect to the trading of the Company’s securities, as well as the securities of publicly traded companies with whom we ha |
|
| March 31, 2025 |
Exhibit 4.7 Description of Registrant’s Securities Predictive Oncology Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), namely, our common stock, par value $0.01 per share (“Common Stock”). Description of Common Stock The following description of our Common Stock is a summary and does not purport t |
|
| March 20, 2025 |
EXHIBIT 99.1 Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences PITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE) - |
|
| March 20, 2025 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) dated as of March 14, 2025 is entered into between Predictive Oncology Inc., a Delaware corporation (“Seller”), and DeRoyal Industries, Inc., a Tennessee corporation (“Buyer”). Capitalized terms used in this Agreement have the meanings given to such terms herein. RECITALS WHEREAS, in addition to its other busine |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 5, 2025 |
Exhibit 10.1 EXTENSION AGREEMENT This Extension Agreement (“Agreement”) is entered into this 28th day of February 2025, by Predictive Oncology, Inc., a Delaware corporation (the “POI”), and Renovaro, Inc. a Delaware corporation (the, “Renovaro”)(collectively, POI and Renovaro may be referred to as the “Parties”). BACKGROUND WHEREAS, POI and Renovaro entered into a definitive Letter agreement dated |
|
| March 5, 2025 |
EXHIBIT 99.1 Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro’s recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology’s bioma |
|
| March 5, 2025 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) |
|
| March 5, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 5, 2025 |
EXHIBIT 99.1 Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro’s recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology’s bioma |
|
| March 5, 2025 |
Exhibit 10.1 EXTENSION AGREEMENT This Extension Agreement (“Agreement”) is entered into this 28th day of February 2025, by Predictive Oncology, Inc., a Delaware corporation (the “POI”), and Renovaro, Inc. a Delaware corporation (the, “Renovaro”)(collectively, POI and Renovaro may be referred to as the “Parties”). BACKGROUND WHEREAS, POI and Renovaro entered into a definitive Letter agreement dated |
|
| February 19, 2025 |
PREDICTIVE ONCOLOGY INC. 363,336 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) File No. 333-279123 PREDICTIVE ONCOLOGY INC. 363,336 Shares of Common Stock We are offering 363,336 shares of our common stock, par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus, directly to institutional investors. Our common stock is listed on The Nasdaq Capital Market under the symbol “POAI.” |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 19, 2025 |
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.1 Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of c |
|
| February 19, 2025 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 19, 2025 |
Form of Securities Purchase Agreement dated February 18, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 18, 2025, between Predictive Oncology Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| February 19, 2025 |
Predictive Oncology Closes Registered Direct Offering EXHIBIT 99.2 Predictive Oncology Closes Registered Direct Offering PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 |
|
| January 13, 2025 |
1,983,302 Shares of Common Stock Issuable Upon Exercise of Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333- 281579 PROSPECTUS 1,983,302 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 1,983,302 shares of our common stock, par value $0.01 per share. These shares consist of (i) 958,117 shares of comm |
|
| January 6, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 6, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 6, 2025 |
Letter of Intent between Predictive Oncology and Renovaro Exhibit 1.01 January 1, 2025 Raymond Vennare Predictive Oncology Inc. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 Confidential Dear Raymond, Thank you very much for the opportunity to review Predictive Oncology Inc. (referred to as the “Company”, “Predictive”, or the “Seller”). We have enjoyed our discussions with you to date and are excited about your business model and prospects and very enco |
|
| January 6, 2025 |
EXHIBIT 99.1 Predictive Oncology Announces Agreement to be Acquired by Renovaro - Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’ interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GL |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabil |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predi |
|
| September 20, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organ |
|
| August 21, 2024 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 August 21, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park, Staff Attorney Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-3, as amended File No. 333-281579 Requested Date: A |
|
| August 15, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| August 15, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on August 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organizat |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 14, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update Company to host investor call and webcast today, August 14th, at 8:30am EDT PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive |
|
| July 29, 2024 |
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds EXHIBIT 99.1 Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its commo |
|
| July 29, 2024 |
EdgarFiling EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF |
|
| July 29, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 29, 2024 |
Form of Placement Agent Warrant EdgarFiling EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF |
|
| July 29, 2024 |
Form of Warrant Inducement Agreement EdgarFiling EXHIBIT 4.4 Predictive Oncology Inc. July 25, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Predictive Oncology Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.000 |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2024 |
EXHIBIT 99.1 Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Study successfully demonstrated Predictive’s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone PIT |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| May 21, 2024 |
Registration No. 333-279123 As filed with the Securities and Exchange Commission on May 21, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of inco |
|
| May 20, 2024 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 May 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park, Staff Attorney Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-3, as amended File No. 333-279123 Requested Date: May |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 8:30am EDT PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tu |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictiv |
|
| May 6, 2024 |
Exhibit 1.2 Execution Version PREDICTIVE ONCOLOGY INC. Common Stock (par value $0.01 per share) ATM Sales Agreement May 3, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Predictive Oncology Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) as follows: 1. Issuance |
|
| May 6, 2024 |
Exhibit 4.43 Predictive Oncology, Inc. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establishment |
|
| May 6, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organization |
|
| May 6, 2024 |
Exhibit 10.1 Execution Version PREDICTIVE ONCOLOGY INC. Common Stock (par value $0.01 per share) ATM Sales Agreement May 3, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Predictive Oncology Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) as follows: 1. Issuanc |
|
| May 6, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on May 3, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organization) |
|
| April 8, 2024 |
Letter of BDO USA, P.C. to the Securities and Exchange Commission, dated April 8, 2024. Exhibit 16.1 Tel: 612-367-3000 Fax: 612-367-3001 www.bdo.com 800 Nicollet Mall, Suite 600 Minneapolis, MN 55402 April 8, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 3, 2024, to be filed by our former client, Predictive Oncology Inc. We agree with the |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 PREDICTIVE ONCOLOGY INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Purpose The purpose of this policy is to set forth the procedures established by the Predictive Oncology (the “Company”) Board of Directors (the “Board”) for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with the financial reporting r |
|
| March 28, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36790 Predictive Oncology Inc. |
|
| March 28, 2024 |
Exhibit 10.9 SEPARATION AGREEMENT AND MUTUAL RELEASE This Separation Agreement and Mutual Release ("Agreement") is made by and between Robert Myers ("Employee") and Predictive Oncology Inc. (the "Company"), each of whom enter into this Agreement intending to be legally bound. 1. Terms of Employment; Separation Date. a. The terms of Employee's employment with the Company are set forth in that certa |
|
| March 22, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 14, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, November 14th, at 8:30am EDT PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc. |
|
| August 10, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 10, 2023 Predictive Oncology Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 2, 2023 |
EXHIBIT 99.1 Predictive Oncology Appoints Pharma, Biotech and Digital Health Veteran Veena Rao, PhD, MBA, to its Board of Directors EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvem |
|
| April 20, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF PREDICTIVE ONCOLOGY INC. (a Delaware corporation) Pursuant to Section 242 of the Delaware General Corporation Law, the undersigned, being the Chief Financial Officer of Predictive Oncology Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that the fo |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 20, 2023 |
EXHIBIT 99.1 Predictive Oncology Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-spli |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 5, 2023 |
Exhibit 16.1 Baker Tilly US, LLP 225 S Sixth St, Ste 2300 Minneapolis, MN 55402-4661 T: +1 (612) 876 4500 F: +1 (612) 238 8900 bakertilly.com April 4, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K, dated on or about April 4, 2023, of Predictive Oncology Inc. and agree with the statements contained in the sec |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 21, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 21, 2023 |
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EXHIBIT 99.1 Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) labora |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 16, 2023 |
Exhibit 3.1 PREDICTIVE ONCOLOGY INC. CERTIFICATE OF DESIGNATION OF SERIES F PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Predictive Oncology Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with the p |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 16, 2023 |
EXHIBIT 99.1 Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0 |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
EXHIBIT 99.1 Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI) |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2023 |
Employment Agreement dated February 23, 2023 by and between Pamela Bush and Predictive Oncology Inc. Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) made and entered into on February 23, 2023, to be effective as of February 1, 2023 (the “Effective Date”) by and between Pamela Bush, an individual, residing at 13418 Canopy Creek Drive, Tampa, Florida 33625 (“Employee”), and Predictive Oncology Inc., 2915 Commers Drive, Suite 900, E |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Inco |
|
| February 3, 2023 |
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer Exhibit 99.1 Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 5, 2022 |
EXHIBIT 99.1 Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company?s strategic initiatives and commercia |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology |
|
| November 10, 2022 |
Predictive Oncology Reports Third Quarter Financial Results Exhibit 99.1 Predictive Oncology Reports Third Quarter Financial Results EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include: Raymond |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 25, 2022 |
Exhibit 99.1 David S. Smith appointed to the Board of Directors of Predictive Oncology Leading authority on the therapeutic use of human tissues and cells EAGAN, Minn., Oct. 25, 2022 (GLOBE NEWSWIRE) – Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran bio |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 20, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) made and entered into effective as of the 1st day of November 2022 (the ?Effective Date?) by and between Raymond F. Vennare, an individual, residing at 179 West Hutchinson Avenue, Pittsburgh, PA 15218, and Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, Minnesota 55121, a Delaware corporation (?Company?), col |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 22, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id |
|
| October 20, 2022 |
EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 September 30, 2022 Raymond Vennare 179 West Hutchinson Avenue Pittsburgh, PA 1528-1321 Dear Raymond: On behalf of Predictive Oncology Inc. (the “Company”), I am very pleased to offer you the position of Chief Executive Officer of Predictive Oncology Inc. This letter establishes the terms of your employment with the Company if you accept this offer. Yo |
|
| October 20, 2022 |
Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth EXHIBIT 99.1 Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth EAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1. As an active member on the POAI Board of Directors since September 2021 |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 13, 2022 |
PREDICTIVE ONCOLOGY INC. 4,737,280 Shares Common Stock Filed pursuant to 424(b)(3) Registration No. 333-267689 PROSPECTUS PREDICTIVE ONCOLOGY INC. 4,737,280 Shares Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 4,737,280 shares of our common stock, par value $0.01 per share. These shares consist of (i) 3,837,280 shares of common stock issuable |
|
| October 11, 2022 |
Predictive Oncology, Inc. 2915 Commers Drive, Suite 900 Eagan, MN 55121 CORRESP 1 filename1.htm Predictive Oncology, Inc. 2915 Commers Drive, Suite 900 Eagan, MN 55121 October 11, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Benjamin Richie Re: Predictive Oncology, Inc. Registration Statement on Form S-1 File No. 333-267689 Ladies and Gentlemen: Pursuant to Rule 461 u |
|
| September 30, 2022 |
Exhibit 3.10 SECOND Amended and Restated BYLAWS of PREDICTIVE ONCOLOGY INC. Effective as of September 9, 2022 ARTICLE 1. OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the Stat |
|
| September 30, 2022 |
S-1 1 fs1093022.htm FORM S-1 Registration No. 333- As filed with the Securities and Exchange Commission on September 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 3842 33-1007393 (State or jurisdiction (Primary |
|
| September 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Predictive Oncology Inc. |
|
| September 16, 2022 |
Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (?Agreement?) is made and entered into effective as of September 15, 2022, by and between J. Melville Engle (?Employee?) and Predictive Oncology Inc., a Delaware corporation (?the Company?), each of whom enter into this Agreement intending to be legally bound. RECITALS The Company and Employee agree upon the |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 16, 2022 |
Predictive Oncology Announces CEO Retirement EXHIBIT 99.1 Predictive Oncology Announces CEO Retirement EAGAN, Minn., Sept. 16, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI) today announced that J. Melville (?Mel?) Engle will retire as Chief Executive Officer and as Chairman and a member of the company?s Board of Directors. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 14, 2022 |
Amendment to Second Amended and Restated Bylaws of Predictive Oncology Inc., dated September 9, 2022 Exhibit 3.1 AMENDMENT TO THE SECOND AMENDED AND RESTATED BYLAWS OF PREDICTIVE ONCOLOGY INC. Pursuant to Article 10 of the Certificate of Incorporation, as amended, of Predictive Oncology Inc., a Delaware corporation (the ?Corporation?), Section 6.06 of the Second Amended and Restated Bylaws of the Corporation (the ?Bylaws?), and Section 109 of the General Corporation Law of the State of Delaware, |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2022 |
Predictive Oncology Reports Second Quarter 2022 Financial Results EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2022 Financial Results EAGAN, Minn., Aug. 11, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt. Highlights from the quarter include: Commercialization la |
|
| August 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc. |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 26, 2022 |
EXHIBIT 99.1 Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm EAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner, Ph.D., as Chief Scientific Of |
|
| July 26, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement ("Agreement") made and entered into effective as of August 1 , 2022 (the "Effective Date") by and between Julia Kirshner, an individual, residing at 1625 Meadowlark Lane, Sunnyvale, CA 94087 ("Employee"), and Predictive Oncology Inc . , 2915 Commers Drive, Suite 900 , Eagan, Minnesota 55121 , a De |
|
| May 25, 2022 |
PREDICTIVE ONCOLOGY INC. 16,671,747 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-254309 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 23, 2021) PREDICTIVE ONCOLOGY INC. 16,671,747 Shares of Common Stock This prospectus supplement (?Supplement?) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus (the ?Prospectus?) filed with the Securities |
|
| May 25, 2022 |
PREDICTIVE ONCOLOGY INC. 5,661,128 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-252584 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 9, 2021) PREDICTIVE ONCOLOGY INC. 5,661,128 Shares of Common Stock This prospectus supplement (?Supplement?) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus (the ?Prospectus?) filed with the Securitie |
|
| May 25, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255582 PROSPECTUS SUPPLEMENT (To Prospectus Supplement June 14, 2021) PREDICTIVE ONCOLOGY INC. 15,520,911 Shares of Common Stock Warrants to Purchase up to 15,520,911 Shares of Common Stock Placement Agent Warrants to Purchase up to 1,164,068 Shares of Common Stock (and the shares of Common Stock underlying such Warrants and Placement Agent War |
|
| May 25, 2022 |
PREDICTIVE ONCOLOGY INC. 1,396,826 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-239851 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 21, 2020) PREDICTIVE ONCOLOGY INC. 1,396,826 Shares of Common Stock This prospectus supplement (?Supplement?) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus (the ?Prospectus?) filed with the Securities a |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 18, 2022 |
PREDICTIVE ONCOLOGY INC. 3,837,280 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated May 5, 2021) File No. |
|
| May 18, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 18, 2022 |
Exhibit 4.3 May 16, 2022 Holder of Warrants to Purchase Common Stock issued on [] Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on or about the date hereof (the ?Offering?) by Predictive Oncology Inc. (the ?Company?) of shares of its common stock, par value $0.01 per share (?Common Stock?) (collectively, the ?Shares?). This letter confirms that, in consid |
|
| May 18, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 16, 2022, between Predictive Oncology Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| May 18, 2022 |
PREDICTIVE ONCOLOGY INC. 8,162,720 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated May 5, 2021) File No. |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 18, 2022 |
Engagement Letter with H.C. Wainwright & Co., dated May 9, 2022 Exhibit 1.1 Execution Version May 9, 2022 STRICTLY CONFIDENTIAL Predictive Oncology Inc. 2915 Commers Drive, Suite 900 Eagan, Minnesota 55121 Attn: J. Melville Engle, Chief Executive Officer Dear Mr. Engle: This letter agreement (this ?Agreement?) constitutes the agreement between Predictive Oncology Inc. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?), that Wainwright shall serve as |
|
| May 18, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 16, 2022, between Predictive Oncology Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| May 18, 2022 |
Predictive Oncology Announces $7.2 Million Registered Direct Offerings EXHIBIT 99.1 Predictive Oncology Announces $7.2 Million Registered Direct Offerings EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (Nasdaq: POAI) (?Predictive Oncology? or ?the Company?), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements wi |
|
| May 18, 2022 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 13, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc |
|
| May 12, 2022 |
Predictive Oncology Reports First Quarter Financial Results EXHIBIT 99.1 Predictive Oncology Reports First Quarter Financial Results EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) - The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31, 2022. The consolidated result |
|
| March 31, 2022 |
Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update EXHIBIT 99.1 Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2021, a period defined by |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2022 |
Exhibit 10.5 PREDICTIVE ONCOLOGY INC. STOCK OPTION AGREEMENT (Employee) This STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into effective as of [?], between Predictive Oncology Inc., a Delaware corporation (the ?Company?) and the undersigned employee (?Employee?). BACKGROUND A. Employee has either been hired to serve as an employee to the Company or the Company desires to induce Emp |
|
| March 31, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2022 |
Exhibit 4.14 Description of Registrant?s Securities As of March 25, 2022, Predictive Oncology Inc. (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), namely, our common stock, par value $0.01 per share (?Common Stock?). Description of Common Stock The following description of our Common Stock is a summary |
|
| March 31, 2022 |
Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Holding Corporation Delaware TumorGenesis Inc. Delaware Soluble Biotech Inc. Delaware Skyline Medical, Inc. Delaware Helomics Intermediate Corporation Delaware Helomics Corporation Delaware zPredicta, Inc. Delaware |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021. |
|
| March 31, 2022 |
Exhibit 10.6 PREDICTIVE ONCOLOGY INC. NON-QUALIFIED STOCK OPTION AGREEMENT (Executive) This STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into effective as of [?] between Predictive Oncology Inc., a Delaware corporation (the ?Company?) and [?] (?Employee?). BACKGROUND A. Employee has either been hired to serve as an employee to the Company or the Company desires to induce Employee t |
|
| March 31, 2022 |
Exhibit 10.7 PREDICTIVE ONCOLOGY INC. NON-QUALIFIED STOCK OPTION AGREEMENT (Director) This STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into effective as of [?], between Predictive Oncology Inc., a Delaware corporation (the ?Company?) and [?]. (?Director?). BACKGROUND A. Director is serving as a member of the board of directors of the Company (the ?Board?) and the Company desires t |
|
| February 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Predictive Oncology Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 7403PM200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
EX-99.3 5 exh993.htm EXHIBIT 99.3 Exhibit 99.3 PREDICTIVE ONCOLOGY INC. UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2021 (Unaudited) Predictive Oncology zPREDICTA Pro Forma Adjustments Note Ref Pro Forma ASSETS Current Assets: Cash and Cash Equivalents $ 41,771,515 $ 440,161 (10,015,941 ) a $ 32,195,735 Accounts Receivable 275,860 76,189 - 351,382 Inventories 397,976 - |
|
| February 10, 2022 |
zPREDICTA, Inc. BALANCE SHEETS Exhibit 99.2 zPREDICTA, Inc. BALANCE SHEETS September 30, 2021 December 31, 2020 (unaudited) (audited) ASSETS Current Assets: Cash $ 440,161 $ 170,141 Accounts Receivable 76,189 51,961 Prepaid Expense and Other Assets 31,267 25,630 Total Current Assets 547,617 247,732 Total Assets $ 547,617 $ 247,732 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts Payable $ 2,877 $ 16,199 Accru |
|
| February 10, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 10, 2022 |
EX-99.1 3 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Independent Auditors' Report To the Stockholders and Board of Directors of zPredicta, Inc. Opinion We have audited the financial statements of zPredicta, Inc. (the Company), which comprise the balance sheets as of December 31, 2020 and 2019, and the related statements of operations, stockholders' equity and cash flows for the years then ended, and the |
|
| January 4, 2022 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2021 Predictive Oncology Inc. (Exact name of registrant as specified in charter) Delaware 001-36790 33-1007393 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| December 27, 2021 |
Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021 EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021 MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders w |
|
| December 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 1, 2021 |
EXHIBIT 99.1 Predictive Oncology Acquires zPREDICTA, Inc. zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology?s Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA?s uniquely designed 3D culture systems create a tumor microenvironment that is closer to the patient?s actual tumor than the currently available alte |
|
| December 1, 2021 |
EX-2.1 2 exh21.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among zPREDICTA, INC. GOLDEN GATE ACQUISITION INC. PREDICTIVE ONCOLOGY INC. and TOM KELLY, AS COMPANY INTEREST REPRESENTATIVE Dated as of November 24, 2021 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of November 24, 2021, by and among Predictive Oncology |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology |
|
| November 10, 2021 |
Predictive Oncology Reports Third Quarter Financial Results EXHIBIT 99.1 Predictive Oncology Reports Third Quarter Financial Results EAGAN, Minn., Nov. 10, 2021 (GLOBE NEWSWIRE) - Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for the quarter ended September 30, 2021. All three of Predictive Oncology?s reportable segments recognized revenue for the quarter, |
|
| November 5, 2021 |
DEF 14A 1 def14a110521.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 15, 2021 |
Predictive Oncology Inc. Announces Newest Board Member EXHIBIT 99.1 Predictive Oncology Inc. Announces Newest Board Member MINNEAPOLIS, Sept. 15, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors, pursuant to action of the Board effectiv |
|
| September 2, 2021 |
Amended and Restated 2012 Stock Incentive Plan (filed herewith) Exhibit 4.1 PREDICTIVE ONCOLOGY INC. AMENDED AND RESTATED 2012 STOCK INCENTIVE PLAN Effective August 10, 2021* TABLE OF CONTENTS 1. Purpose 3 2. Administration 3 3. Eligible Participants 3 4. Types of Incentives 3 5. Shares Subject to the Plan 4 5.1. Number of Shares 4 5.2. Cancellation 4 5.3. Type of Common Stock 4 5.4. Limitation on Awards Granted to Non-Employee Directors 4 6. Stock Options 4 6 |
|
| September 2, 2021 |
Registration No. 333- As filed with the Securities and Exchange Commission on September 2, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PREDICTIVE ONCOLOGY INC. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction of 2915 Commers Drive, Suite 900 Eagan |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 19, 2021 |
Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting EXHIBIT 99.1 Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting MINNEAPOLIS, Aug. 18, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, announced today that on August 17, 2021, the stockholders approved an amendment to the Company? |
|
| August 19, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF PREDICTIVE ONCOLOGY INC. (A Delaware Corporation) Pursuant to Section 242 of the Delaware General Corporation Law, the undersigned, being the Chief Financial Officer of Predictive Oncology Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), does hereby certify that the fo |
|
| August 12, 2021 |
Predictive Oncology Adjourns Special Meeting of Stockholders EXHIBIT 99.1 Predictive Oncology Adjourns Special Meeting of Stockholders MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, announced today that the Company?s Special Meeting of Stockholders, which was convened at 3:00 p.m. Central Time on Augus |
|
| August 12, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 11, 2021 |
EXHIBIT 99.1 Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc. |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 7, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 16, 2021 |
Exhibit 4.2 Placement Agent COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY INC. Warrant Shares: Issue Date: , 2021 THIS Placement Agent COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authoriz |
|
| June 16, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 14, 2021, between Predictive Oncology Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| June 16, 2021 |
Exhibit 99.1 Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules June 14, 2021 MINNEAPOLIS, June 14, 2021 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (?Predictive Oncology? or ?the Company?), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, today anno |
|
| June 16, 2021 |
Amendment to Engagement Letter Exhibit 1.2 June 15, 2021 STRICTLY CONFIDENTIAL Predictive Oncology Inc. 2915 Commers Drive, Suite 900 Eagan, Minnesota 55121 Attn: J. Melville Engle, Chief Executive Officer Dear Mr. Engle: Reference is made to that certain engagement agreement (the ?Engagement Agreement?), dated as of January 7, 2021, by and between Predictive Oncology Inc. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwr |
|
| June 16, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY INC. Warrant Shares: Issue Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date (the ?Ini |
|
| June 16, 2021 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated May 5, 2021) File No. |
|
| June 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 20, 2021 |
Exhibit 10.1 Predictive Oncology Inc. (POAI) 2021 Long-Term Incentive Plan (LTIP) Effective May 17, 2021 Goals of Long-Term Incentive Plan Long-Term Incentive Plan (LTIP) awards are intended to reward senior executives in a manner that aligns remuneration with the creation of shareholder wealth. Under the LTIP, the CEO and CFO, are being granted equity awards under the Amended and Restated 2012 St |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2021 Predictive Oncology Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2021 |
EXHIBIT 99.1 Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business Update MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 |
|
| May 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 3, 2021 |
May 3, 2021 BY EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| April 28, 2021 |
Registration No. 333- As filed with the Securities and Exchange Commission on April 28, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organizati |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 21, 2021 Predictive Oncology Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 27, 2021 |
Predictive Oncology Inc. Announces Newest Board Member EXHIBIT 99.1 Predictive Oncology Inc. Announces Newest Board Member MINNEAPOLIS, April 27, 2021 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (?AI?) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins. Dr. Christina Jenkins is a strategic advisor and |
|
| April 7, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) made and entered into effective as of the 19th day of March 2021 (the ?Effective Date?) by and between J. Melville Engle, an individual, residing at 8778 E. 152nd Place, Thornton, CO 80602 (?Employee?), and Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, Minnesota 55121, a Delaware corporation (?Company?), co |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 24, 2021 |
PREDICTIVE ONCOLOGY INC. 16,671,747 Shares Common Stock Filed Pursuant to Rule 424(b)(3) File No. 333-254309 PREDICTIVE ONCOLOGY INC. 16,671,747 Shares Common Stock This prospectus relates to the offer and resale of up to 16,671,747 shares of our common stock, par value $0.01 per share, by the selling stockholders as listed in the selling stockholders table on page 15 (the ?Selling Stockholders?). For more information about the Selling Stockholders, pl |
|
| March 23, 2021 |
Predictive Oncology Inc. Announces New CEO Exhibit 99.1 Predictive Oncology Inc. Announces New CEO Minneapolis, March 23 2021 - Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J. Melville (“Mel”) Engle as Chief Executive Officer of the company. In addition to being named CEO, Mr. Engl |
|
| March 23, 2021 |
Exhibit 10.3 March 19, 2021 Mr. J. Melville Engle 8778 E. 152nd Place Thornton, CO 80602 Dear Mel: On behalf of Predictive Oncology, Inc. (the ?Company?), I am very pleased to offer you the position of Chief Executive Officer of Predictive Oncology, Inc. This letter establishes the terms of your employment with the Company if you accept this offer. You will remain Chairman of the Board unless othe |
|
| March 23, 2021 |
Registration No. 333-254309 As filed with the Securities and Exchange Commission on March 23, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of in |
